Premium
Azithromycin as an adjunct to scaling and root planing in the treatment of Porphyromonas gingivalis ‐associated periodontitis: a pilot study
Author(s) -
Oteo Alfonso,
Herrera David,
Figuero Elena,
O'Connor Ana,
González Itziar,
Sanz Mariano
Publication year - 2010
Publication title -
journal of clinical periodontology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.456
H-Index - 151
eISSN - 1600-051X
pISSN - 0303-6979
DOI - 10.1111/j.1600-051x.2010.01607.x
Subject(s) - medicine , scaling and root planing , azithromycin , porphyromonas gingivalis , placebo , chronic periodontitis , periodontitis , confidence interval , randomized controlled trial , gastroenterology , dentistry , antibiotics , pathology , microbiology and biotechnology , biology , alternative medicine
Oteo A, Herrera D, Figuero E, O'Connor A, González I, Sanz M. Azithromycin as an adjunct to scaling and root planing in the treatment of Porphyromonas gingivalis ‐associated periodontitis: a pilot study. J Clin Peridontol 2010; 37: 1005–1015. doi: 10.1111/j.1600‐051X.2010.01607.x. Abstract Objective: To evaluate the clinical and microbiological effects of systemic azithromycin as an adjunct to scaling and root planing (SRP) in the treatment of Porphyromonas gingivalis ‐associated chronic periodontitis. Methods: Twenty‐nine patients harbouring P. gingivalis were randomized into test and placebo groups. Test patients received SRP plus 500 mg of azithromycin per day (3 days), and control patients received SRP plus placebo. Clinical [plaque and bleeding indexes, probing pocket depth (PPD), clinical attachment level (CAL)] and microbiological data (four‐sites pooled samples, processed by culture) were collected at baseline, and 1, 3 and 6 months, post‐therapy. Clinical variables were compared by anova , and microbiological variables by chi‐square, signed‐rank and Wilcoxon tests. Results: Fifteen test and 11 placebo patients completed the study. Mean PPD decreased 0.34 mm [95% confidence interval (CI) 0.19–0.49] in the placebo and 0.80 mm (CI 0.57–1.04) in the test group after 6 months. For mean CAL gain, the correspondent figures were 0.29 (CI 0.08–0.49) and 0.76 (CI 0.46–1.05), respectively. The frequency of detection of P. gingivalis decreased significantly ( p 0.01) in the test group after 1, 3 and 6 months. Conclusions: Within the limitations of this study, the adjunctive use of systemic azithromycin in the treatment of P. gingivalis periodontitis demonstrated significant clinical and microbiological benefits when compared with SRP plus placebo.